Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03.
Anavex Life Sciences Price Performance
AVXL stock traded down $0.21 during mid-day trading on Wednesday, reaching $9.70. 579,672 shares of the company traded hands, compared to its average volume of 1,896,226. The company has a market capitalization of $822.72 million, a P/E ratio of -18.65 and a beta of 0.70. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $14.44. The company has a fifty day moving average price of $9.98 and a 200-day moving average price of $7.51.
Analyst Ratings Changes
A number of analysts recently weighed in on the company. D. Boral Capital restated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research note on Tuesday.
Get Our Latest Report on AVXL
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Recommended Stories
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
